Cargando…
Comment on “Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy”
We recently read with interest the original research article entitled "Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy". The abovementioned article is an observational retrospective cohort study, which could be...
Autores principales: | Argyriou, Konstantinos, Kotsakis, Athanasios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403700/ https://www.ncbi.nlm.nih.gov/pubmed/36159549 http://dx.doi.org/10.12998/wjcc.v10.i23.8425 |
Ejemplares similares
-
Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy
por: Rubin, Samuel J S, et al.
Publicado: (2022) -
Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease
por: Weingarden, Alexa R, et al.
Publicado: (2021) -
Comment on “Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease”
por: Lai, Wenwen, et al.
Publicado: (2018) -
Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2020) -
Evidence-based considerations on bowel preparation for colonoscopy
por: Argyriou, Konstantinos, et al.
Publicado: (2022)